Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy

Journal of Medical Virology

Volumn 80, Issue 9, 2008, Pages 1595-1603

  Ulasov, Ilya V ^a   Tyler, Matthew A ^a   Rivera, Angel A ^b   Nettlebeck, Dirk M ^c   Douglas, Joanne T ^b   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Ad2 24; Adenovirus; Gene therapy; Glioma; Oncolytic virus; Virotherapy

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; E1A PROTEIN; HISTONE ACETYLTRANSFERASE PCAF; ONCOLYTIC ADENOVIRUS; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOLYSIS; CYTOPATHOGENIC EFFECT; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SPECIFICITY; EMBRYO; FLOW CYTOMETRY; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN BINDING; QUANTITATIVE ANALYSIS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS MUTATION; VIRUS REPLICATION; WESTERN BLOTTING; WILD TYPE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; CELL LINE; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; MUTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 48249085659     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21264     Document Type: Article

References (42)

1. Babiss LE, Ginsberg HS, Darnell JE, Jr. 1985. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol Cell Biol 5:2552-2558.
2. Baluchamy S, Sankar N, Navaraj A, Moran E, Thimmapaya B. 2007. Relationship between E1A binding to cellular proteins, c-myc activation and S-phase induction. Oncogene 26:781-787.
3. Bandara LR, La Thangue NB. 1991. Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Nature 351:494-497.
4. Banerjee NS, Rivera AA, Wang M, Chow LT, Broker TR, Curiel DT, Nettelbeck DM. 2004. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther 3:437-449.
5. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. 1991. The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053-1061.
6. Cherubini G, Petouchoff T, Grossi M, Piersanti S, Cundari E, Saggio I. 2006. E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. Cell Cycle 5: 2244-2252.
7. Chow KN, Starostik P, Dean DC. 1996. The Rb family contains a conserved cyclin-dependent-kinase-regulated transcriptional repressor motif. Mol Cell Biol 16:7173-7181.
8. de Bouard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo JS. 2007. Antiangiogenic and antiinvasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 9:412-423.
9. Debbas M, White E. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7:546-554.
10. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A, Kim JH. 2007. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15:1016-1023.
11. Frisch SM, Mymryk JS. 2002. Adenovirus-5 E1A: Paradox and paradigm. Nat Rev Mol Cell Biol 3:441-452.
12. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. 2000. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19:2-12.
13. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. 2003. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95:652-660.
14. Gallimore PH, Turnell AS. 2001. Adenovirus E1A: Remodelling the host cell, a life or death experience. Oncogene 20:7824-7835.
15. Ghosh MK, Harter ML. 2003. A viral mechanism for remodeling chromatin structure in G0 cells. Mol Cell 12:255-260.
16. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. 2006. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12:556-562.
17. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639-645.
18. Hitt MM, Graham FL. 1990. Adenovirus E1A under the control of heterologous promoters: Wide variation in E1A expression levels has little effect on virus replication. Virology 179:667-678.
19. Kangasniemi L, Kiviluoto T, Kanerva A, Raki M, Ranki T, Sarkioja M, Wu H, Marini F, Hockerstedt K, Isoniemi H, Alfthan H, Stenman UH, Curiel DT, Hemminki A. 2006. Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin Cancer Res 12:3137-3144.
20. Kasparov S. 2007. Suitability of hCMV for viral gene expression in the brain. Nat Methods 4:379; author reply 379.
21. Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ, Curiel DT. 2004. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 10: 8697-8703.
22. Kirn D. 2001. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther 8:89-98.
23. Kirn D, Martuza RL, Zwiebel J. 2001. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7:781-787.
24. Knudsen ES, Wang JY. 1996. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 271:8313-8320.
25. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Andersen AP, Eigen K. 1981. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47:649-652.
26. Lockley M, Fernandez M, Wang Y, Li NF, Conroy S, Lemoine N, McNeish I. 2006. Activity of the adenoviral E1A deletion mutant dl922-947in ovarian cancer: Comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res 66:989-998.
27. Mittereder N, March KL, Trapnell BC. 1996. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70:7498-7509.
28. Nakagawa K, Aoki Y, Fujimaki T, Tago M, Terahara A, Karasawa K, Sakata K, Sasaki Y, Matsutani M, Akanuma A. 1998. High-dose conformai radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40:1141-1149.
29. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. 2002. Novel oncolytic adenoviruses targeted to melanoma: Specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 62:4663-4670.
30. Nevins JR. 1992. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429.
31. Preuss MA, Lam JT, Wang M, Leath CA, III, Kataram M, Mahasreshti PJ, Alvarez RD, Curiel DT. 2004. Transcriptional blocks limit adenoviral replication in primary ovarian tumor. Clin Cancer Res 10:3189-3194.
32. Pulliam L, Berens ME, Rosenblum ML. 1988. A normal human brain cell aggregate model for neurobiological studies. J Neurosci Res 21:521-530.
33. Rasti M, Grand RJ, Mymryk JS, Gallimore PH, Turnell AS. 2005. Recruitment of CBP/p300, TATA-binding protein, and S8 to distinct regions at the N terminus of adenovirus E1A. J Virol 79:5594-5605.
34. Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, Nettelbeck DM. 2004. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 11:1694-1702.
35. Sauthoff H, Pipiya T, Heitner S, Chen S, Bleck B, Reibman J, Chang W, Norman RG, Rom WN, Hay JG. 2004. Impact of E1a modifications on tumor-selective adenoviral replication and toxicity. Mol Ther 10:749-757.
36. Sehgal A, Ricks S, Boynton AL, Warrick J, Murphy GP. 1998. Molecular characterization of CXCR-4: A potential brain tumor-associated gene. J Surg Oncol 69:239-248.
37. Sonabend AM, Ulasov TV, Lesniak MS. 2007. Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mo Biol 11:79-92.
38. Sonabend AM, Ulasov TV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS. 2008. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26:831-841.
39. Svensson C, Bondesson M, Nyberg E, Linder S, Jones N, Akusjarvi G. 1991. Independent transformation activity by adenovirus-5 E1A-conserved regions 1 or 2 mutants. Virology 182:553-561.
40. Weinberg RA. 1992. The retinoblastoma gene and gene product. Cancer Surv 12:43-57.
41. Yew PR, Berk AJ. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357:82-85.
42. Zamanian M, La Thangue NB. 1992. Adenovirus E1a prevents the retinoblastoma gene product from repressing the activity of a cellular transcription factor. EMBO J 11:2603-2610.